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Abstract Xenobiotic phase I and II reactions generally render a compound more water soluble and pharmacologically
inactive, thereby eliminating the need for further evaluation. However, if the metabolite forms a toxic compound such as
acylglucuronide additional safety assessment may be needed. Glucuronidation is the most common pathway for detoxification
and elimination of hydrophobic xenobiotics in mammals. Thus, development of an efficient in vitro synthesis of glucuronides
from parent drugs often becomes critical during studies of drug metabolism undertaken in the development of a new
pharmaceutical product. In order to produce glucuronides as drug metabolites, we have developed coexpression systems for
mammalian cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT), and UDP-glucose dehydrogenase in
Saccharomyces cerevisiae cells, and combination between each of human CYPs and UGTs was achieved. Glucuronide
formation in yeast cells was performed in reaction medium containing 8% glucose, and most of glucuronides were readily
recovered from cell medium. In addition, we have expressed human sulfotransferase (SULT) with CYPs in Saccharomyces
cerevisiae cells, and successfully obtained sulfoconjugates from the cell medium. In conclusion, our coexpression systems
have made it possible to produce human phase I and phase II metabolites in the milligram to gram scale.
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和文抄録
医薬品をはじめとする多くの生体外異物は抱合体
代謝物となり水溶性を増すことで体外へ解毒排泄され
るが、一部の医薬品抱合体は反応性代謝物となり副作
用を惹起する。新規医薬品の開発段階における抱合代
謝物の安全性・機能性評価は極めて重要である。本発
表では抱合体を簡便に調製することを目的として、出
芽酵母に薬物代謝酵素を発現させることで、酵母菌体
に添加した基質の抱合体への効率的な変換を試みた。
抱合反応の代表的なものとしてはグルクロン酸抱合お
よび硫酸抱合があり、それぞれ UDP-グルクロン酸転移
酵素(UGT)と硫酸基転移酵素(SULT)により触媒される。
ヒト及び実験動物 UGTや SULT分子種をそれぞれ発現す
る酵母株を作製し、数種の医薬品の部位特異的なグル
クロン酸抱合体および硫酸抱合体の産生を可能にした。
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